Analystreport

Akero Therapeutics (NASDAQ:AKRO) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.

Akero Therapeutics, Inc.  (AKRO) 
Last akero therapeutics, inc. earnings: 3/16 07:30 am Check Earnings Report